Trial Profile
A Randomized, Double-blinded, Single-dose, 3-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT1806 Injection vs Actemra in Healthy Chinese Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2023
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Bio-Thera Solutions
- 05 Jun 2023 Primary endpoint (Pharmacokinetics Endpoint) has been met, according to a Dr Reddys Laboratories.
- 16 Nov 2021 Status changed from active, no longer recruiting to completed.
- 11 Jan 2019 Planned primary completion date changed from 30 Nov 2018 to 30 Mar 2019.